These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38740147)

  • 1. Proteogenomic analysis identifies neoantigens and bacterial peptides as immunotherapy targets in colorectal cancer.
    Yao P; Gao M; Hu W; Wang J; Wang Y; Wang Q; Ji J
    Pharmacol Res; 2024 Jun; 204():107209. PubMed ID: 38740147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteogenomic identification of an immunogenic HLA class I neoantigen in mismatch repair-deficient colorectal cancer tissue.
    Hirama T; Tokita S; Nakatsugawa M; Murata K; Nannya Y; Matsuo K; Inoko H; Hirohashi Y; Hashimoto S; Ogawa S; Takemasa I; Sato N; Hata F; Kanaseki T; Torigoe T
    JCI Insight; 2021 Jul; 6(14):. PubMed ID: 34185709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment.
    Newey A; Griffiths B; Michaux J; Pak HS; Stevenson BJ; Woolston A; Semiannikova M; Spain G; Barber LJ; Matthews N; Rao S; Watkins D; Chau I; Coukos G; Racle J; Gfeller D; Starling N; Cunningham D; Bassani-Sternberg M; Gerlinger M
    J Immunother Cancer; 2019 Nov; 7(1):309. PubMed ID: 31735170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A proteogenomic approach to target neoantigens in solid tumors.
    Verma A; Halder A; Marathe S; Purwar R; Srivastava S
    Expert Rev Proteomics; 2020; 17(11-12):797-812. PubMed ID: 33491499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoantigen: A Promising Target for the Immunotherapy of Colorectal Cancer.
    Zheng Y; Fu Y; Wang PP; Ding ZY
    Dis Markers; 2022; 2022():8270305. PubMed ID: 35211210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrent Neoantigens in Colorectal Cancer as Potential Immunotherapy Targets.
    Chen C; Liu S; Qu R; Li B
    Biomed Res Int; 2020; 2020():2861240. PubMed ID: 32733937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoantigen-reactive T cells exhibit effective anti-tumor activity against colorectal cancer.
    Yu Y; Zhang J; Ni L; Zhu Y; Yu H; Teng Y; Lin L; Xue Z; Xue X; Shen X; Song H; Su X; Sun W; Cai Z
    Hum Vaccin Immunother; 2022 Dec; 18(1):1-11. PubMed ID: 33689574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteogenomic discovery of neoantigens facilitates personalized multi-antigen targeted T cell immunotherapy for brain tumors.
    Rivero-Hinojosa S; Grant M; Panigrahi A; Zhang H; Caisova V; Bollard CM; Rood BR
    Nat Commun; 2021 Nov; 12(1):6689. PubMed ID: 34795224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A method of screening highly common neoantigens with immunogenicity in colorectal cancer based on public somatic mutation library].
    Qin LL; Li YJ; Liang ZR; Dai L; Li WH; Chen C; Huang YL; Zhang L; Liu SM; Qiu S; Ge YP; Peng WT; Lin XX; Zhang XQ; Dong X; Li B
    Yi Chuan; 2020 Jun; 42(6):599-612. PubMed ID: 32694118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4.
    van den Bulk J; Verdegaal EME; Ruano D; Ijsselsteijn ME; Visser M; van der Breggen R; Duhen T; van der Ploeg M; de Vries NL; Oosting J; Peeters KCMJ; Weinberg AD; Farina-Sarasqueta A; van der Burg SH; de Miranda NFCC
    Genome Med; 2019 Dec; 11(1):87. PubMed ID: 31888734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of mass spectrometry-based MHC immunopeptidome profiling in neoantigen identification for tumor immunotherapy.
    Zhang X; Qi Y; Zhang Q; Liu W
    Biomed Pharmacother; 2019 Dec; 120():109542. PubMed ID: 31629254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens.
    Linette GP; Becker-Hapak M; Skidmore ZL; Baroja ML; Xu C; Hundal J; Spencer DH; Fu W; Cummins C; Robnett M; Kaabinejadian S; Hildebrand WH; Magrini V; Demeter R; Krupnick AS; Griffith OL; Griffith M; Mardis ER; Carreno BM
    Proc Natl Acad Sci U S A; 2019 Nov; 116(47):23662-23670. PubMed ID: 31685621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional analysis of peripheral and intratumoral neoantigen-specific TCRs identified in a patient with melanoma.
    Bräunlein E; Lupoli G; Füchsl F; Abualrous ET; de Andrade Krätzig N; Gosmann D; Wietbrock L; Lange S; Engleitner T; Lan H; Audehm S; Effenberger M; Boxberg M; Steiger K; Chang Y; Yu K; Atay C; Bassermann F; Weichert W; Busch DH; Rad R; Freund C; Antes I; Krackhardt AM
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34518289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COSMIC-based mutation database enhances identification efficiency of HLA-I immunopeptidome.
    Wang F; Zhang Z; Mao M; Yang Y; Xu P; Lu S
    J Transl Med; 2024 Feb; 22(1):144. PubMed ID: 38336780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer.
    Picard E; Verschoor CP; Ma GW; Pawelec G
    Front Immunol; 2020; 11():369. PubMed ID: 32210966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoantigens in Hematological Malignancies-Ultimate Targets for Immunotherapy?
    Roerden M; Nelde A; Walz JS
    Front Immunol; 2019; 10():3004. PubMed ID: 31921218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ProGeo-neo: a customized proteogenomic workflow for neoantigen prediction and selection.
    Li Y; Wang G; Tan X; Ouyang J; Zhang M; Song X; Liu Q; Leng Q; Chen L; Xie L
    BMC Med Genomics; 2020 Apr; 13(Suppl 5):52. PubMed ID: 32241270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes.
    Gros A; Tran E; Parkhurst MR; Ilyas S; Pasetto A; Groh EM; Robbins PF; Yossef R; Garcia-Garijo A; Fajardo CA; Prickett TD; Jia L; Gartner JJ; Ray S; Ngo L; Wunderllich JR; Yang JC; Rosenberg SA
    J Clin Invest; 2019 Nov; 129(11):4992-5004. PubMed ID: 31609250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
    Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
    J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utilizing immunogenomic approaches to prioritize targetable neoantigens for personalized cancer immunotherapy.
    Shah RK; Cygan E; Kozlik T; Colina A; Zamora AE
    Front Immunol; 2023; 14():1301100. PubMed ID: 38149253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.